Insider Buying: Immuneering (NASDAQ:IMRX) Insider Purchases 2,298 Shares of Stock

Immuneering Corporation (NASDAQ:IMRX) insider Brett Matthew Hall acquired 2,298 shares of the firm’s stock in a transaction that occurred on Thursday, January 15th. The shares were bought at an average price of $4.57 per share, with a total value of $10,501.86. Following the acquisition, the insider directly owned 376,496 shares of the company’s stock, valued at $1,720,586.72. The trade was a 0.61% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Immuneering Stock Performance

NASDAQ:IMRX traded down $0.06 during trading hours on Friday, reaching $4.58. The stock had a trading volume of 1,571,491 shares, compared to its average volume of 4,332,983. The stock has a 50 day simple moving average of $6.41 and a 200 day simple moving average of $5.77. Immuneering Corporation has a 12-month low of $1.10 and a 12-month high of $10.08. The stock has a market cap of $295.73 million, a P/E ratio of -2.57 and a beta of 0.48.

Immuneering (NASDAQ:IMRX) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). On average, equities analysts expect that Immuneering Corporation will post -1.86 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Immuneering

A number of institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC bought a new position in shares of Immuneering during the first quarter valued at approximately $32,000. China Universal Asset Management Co. Ltd. bought a new position in Immuneering during the 3rd quarter valued at approximately $35,000. Future Financial Wealth Managment LLC bought a new position in Immuneering during the 3rd quarter valued at approximately $35,000. Kingsview Wealth Management LLC purchased a new position in Immuneering during the second quarter valued at $47,000. Finally, Mercer Global Advisors Inc. ADV bought a new stake in Immuneering in the third quarter worth $70,000. 67.65% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

IMRX has been the topic of several research reports. Leerink Partnrs upgraded shares of Immuneering to a “strong-buy” rating in a research report on Friday, October 31st. Mizuho set a $12.00 target price on Immuneering in a research note on Wednesday, October 29th. HC Wainwright restated a “buy” rating and set a $11.00 price target on shares of Immuneering in a research report on Tuesday, September 30th. Wall Street Zen cut Immuneering from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Immuneering in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $16.50.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.